Press release
2019-03-07
Xbrane Biopharma informs that the company presentation will be scheduled earlier than previously communicated. The starting time of the presentation will be at 18.00.
To see the live broadcast, follow the link below;
Registration to this event is made by following the link below;
About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long-acting injectables. Xbrane has world leading expertise in developing generics for long-acting injectable drugs and proprietary high-yield protein expression technology for the development of biosimilars. Xbrane's headquarter is located in Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane's certified adviser. For more information see www.xbrane.com.
For further information, please contact:
Martin Åmark
CFO / IR
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com
Susanna Helgesen
CFO
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com
